Table 3.

Efficacy of Gefitinib-based therapy vs. control according to EGFR mutation status and histology

Study	PFS	P value	Study	OS	P value
	HR (95% CI)			HR (95% CI)
EGFR mutant
Bell et al. 2005[6]	0.55 (0.19–1.60)		Bell et al. 2005[6]	1.77 (0.50–6.25)
Crino et al. 2008[18]	3.13 (1.45–6.76)		Crino 2008[18]	2.88 (1.21–6.85)
Goss et al. 2009[19]	0.29 (0.11–0.75)		Goss et al. 2009[19]	0.44 (0.17–1.13)
Mok et al. 2009[9]	0.48 (0.36–0.64)		Mok et al. 2009[9]	0.78 (0.49–1.23)
Subtotal	0.71 (0.27–1.85)	0.48		1.10 (0.51–2.40)	0.81
EGFR wild
Bell et al. 2005[6]	0.73 (0.53–1.01)		Bell et al. 2005[6]	0.91 (0.76–1.23)
Goss et al. 2009[19]	0.74 (0.38–1.45)		Goss et al. 2009[19]	1.02 (0.56–1.87)
Mok et al. 2009[9]	2.85 (2.05–3.97)		Mok et al. 2009[9]	1.38 (0.92–2.08)
Subtotal	1.17 (0.43–3.19)	0.76		1.06 (0.81–1.39)	0.65
Total	0.89 (0.45–1.76)	0.74		1.06 (0.77–1.47)	0.71
Adenocarcinoma
			Herbst et al. 2004[5]
			500 mg	1.03 (0.81–1.31)
			250 mg	1.16 (0.90–1.48)
			Takeda et al. 2010[16]	0.79 (0.64–0.97)
Subtotal				0.97 (0.77–1.22)	0.81
Non-adenocarcinoma
			Herbst et al. 2004[5]
			500 mg	0.74 (0.52–1.04)
			250 mg	0.92 (0.64–1.32)
			Takeda et al. 2010[16]	1.24 (0.85–1.80)
Subtotal				0.94 (0.70–1.26)	0.67
Total				0.96 (0.81–1.13)	0.60